Various inhibitors have been developed for neuraminidase but resistance against these drugs in many viral strains makes it an advantageous and interesting task to discover compounds which can be more promising in preventing viral infection through neuraminidase. Virtual screening methods have been proved as an efficient in silico approach for drug discovery processes. In the present study, we used ligand based virtual screening process for identifying potent inhibitors against viral neuraminidase enzyme. The approach utilized in this study has been successful in identifying 15 compounds which may be potential inhibitors of neuraminidase. These compounds were screened via three screening platforms (MVD, PyRx, and FRED) by setting oseltamivir as reference compound, which is an FDA approved drug against influenza virus. These compounds were then filtered by their in silico ADME/T (Absorption, Distribution, Metabolism, Excretion, and Toxicity) values and only 12 of them were found to have comparatively better results. The results of the present study are reported herein so that researchers, who are having required laboratory facilities for synthesizing drugs, can utilize findings of this study for developing new drugs against influenza with better efficacy.
Introduction
Some of the reported worst epidemics in the history of humans have been caused by influenza viruses. Influenza viruses contain two major glycoproteins attached on their surface: haemagglutinin (HA) and neuraminidase (NA). Haemagglutinin helps virus in the attachment and penetration of host cells via sialic acid binding sites [1, 2] and neuraminidase enzymatically cleaves bonding between haemagglutinin and sialic acid from cell surface glycoconjugates and thus facilitates the release of progeny virions from infected cells, spreads the new virus particles, and prevents the aggregation of progeny virions [3, 4] . According to different antigenic properties of haemagglutinin and neuraminidase molecules, influenza type A viruses can be classified into 16 subtypes by haemagglutinin (H1-H16) and 9 subtypes by neuraminidase (N1-N9) [5] . Numerous combinations of haemagglutinin and neuraminidase subtypes have been found in influenza type A viruses on avian species, i.e. bird flu. Among them, H5N1 has received extensive attention in recent years since it has caused a considerable number of human lives worldwide [6] .
In theory, both haemagglutinin and neuraminidase can be considered as therapeutic targets for preventing the replication and spread of influenza viruses in host cells. Although the crystal structure of haemagglutinin was already resolved in early 1980s [7] , no tightly binding compounds have been discovered for it. As for neuraminidase, many inhibitors with high potencies have been developed. For example, zanamivir and oseltamivir (Tamiflu) are two successful drugs currently in use [8, 9] . Nevertheless, resistance against these drugs has subsequently been developed by influenza viruses, still making the development of new classes of neuraminidase inhibitors a significant and urgent task [10, 11] . Neuraminidase was chosen as a suitable drug target because NA plays a major role in influenza virus propagation, and the amino acid residues of the active site interacting directly with the substrate or surrounding the central active site of the enzyme are strictly conserved [12] .
Virtual screening (VS) is considered as computational approach of high throughput screening (HTS) and refers to the in silico evaluation of properties of different molecular scaffolds including binding affinity, interaction energy, etc. Different applications of machine learning to virtual screening have been presented in the literature including both ligand-based similarity searching and structure-based docking. The main purpose of such applications is to prioritize databases of molecules as active against a particular protein target. Some case studies presented in the same perspective suggest that VS has already played a significant role in the discovery of some compounds that are now in the clinical trial or even in the market [13] [14] [15] [16] [17] [18] .
Materials and methods

Selection and preparation of target/receptor protein for docking
Target neuraminidase protein (PDB ID: 2HU0) was obtained from the Protein Data Bank (PDB) which is a repository for the 3-D structural data of large biologi- cal molecules [19] . This protein was selected as target because the observation of the open conformation for the 150-loop in the group-1 structures suggests that, for these enzymes, this conformation of the loop is intrinsically lower in energy than the closed conformation. Group-1 neuraminidases (N1 and N8) initially bind to oseltamivir in this open conformation but eventually adopt the closed conformation. It thus seems that oseltamivir binding to group-1 neuraminidases favors the higher energy or closed conformation of the 150-loop that it probably accesses via a relatively slow conformational change. It should therefore be possible to design new inhibitors for group-1 neuraminidases that are selective for the open 150-loop conformation and would thereby have the potential to bind more strongly than oseltamivir or zanamivir [20] .
Cavity detection and selection
Possible active site(s)/cavities for the target protein (2HU0) of interest were determined with the help of Molegro Virtual Docker (MVD) [21] . A number of cavities were detected for the same protein but only one cavity was selected as active site on the basis of prior information about the active site residues, available in literatures. This cavity was utilized in further docking studies.
Ligand screening from ZINC database (version 12)
Ligands were screened from ZINC database on the basis of structural similarity with known neuraminidase inhibitors (oseltamivir, zanamivir, peramivir and laninamivir) [22] [23] [24] [25] . 70% structural similarity was used as cut off for database screening. On the basis of oseltamivir, zanamivir, peramivir and laninamivir 30, 57, 3, and 58 analogs were found respectively. Out of 58 analogs of laninamivir 57 were common for both lan-inamivir and zanamivir and one was different (ZINC ID 71974042), common analogs were considered only once.
Results and discussion
Active site analysis
The active sites of all influenza neuraminidases contain three arginine residues -Arg118, Arg292 and Arg371 -that bind the carboxylate of the substrate sialic acid, one arginine residue, Arg152, interacts with the acetamido substituent of the substrate, and one glutamine residue, Glu276, forms hydrogen bonds with the 8-and 9-hydroxyl groups of the substrate [20] . Binding pocket of NA, as predicted by MVD and supported by various literatures, is given in Fig. 1 along with their amino acid residues.
Selection, validation and evaluation of docking protocol
In molecular docking, validation of docking protocol is a necessary step in order to ensure that ligands bind within the binding pocket in the correct conformation which is done by validating the size and center of the coordinates of the grid box across the binding pocket [26] . In this work, docking protocol was validated by redocking co-crystallized structure of neuraminidase in complex with oseltamivir (PDB ID: 2HU0). During redocking various algorithms were used which are available in MVD and it was observed that most suited algorithm was MolDock SE (Simplex Evolution) search algorithm. All binding conformations of redocked oseltamivir within the binding pocket of NA produced by MolDock SE algorithm were similar to binding mode of the co-crystallized ligand, and the root mean square deviation (RMSD) for these conformations were below 2Å [27] . The RMSD of best pose was 1.75Å, interaction energy (between target protein and ligand) was −100.69 kcal/mol and hydrogen bond energy was −11.69 kcal/mol, Fig. 2 .
Analysis of interactions and binding poses of known inhibitors
All the four known inhibitors were re-docked within the binding pocket of neuraminidase and their Table 2 Comparative chart for ADME/T values of screened compound along with reference compound oseltamivir (RC1). interactions were analyzed with the help of MVD, Fig. 3A -D.
Docking study for screening of unknown inhibitors
All the 91 different analogs of known inhibitors that were screened from ZINC database were docked within the binding pocket of neuraminidase with the help of Molegro Virtual Docker, PyRx (Autodock Vina) and FRED [21, [28] [29] [30] . Only those compounds were selected after screening that showed positive result from all the three docking platforms and were having better binding affinity, docking score, similarity with the known inhibitors and other scoring functions ( Table 1) . Poses for the unknown inhibitors were evaluated on the basis of various factors such as by comparing their hydrogen bonding interaction patterns and overall interaction overlay with the known inhibitors, etc.
ADME/T studies
APOD (abbreviated profile of drugs) calculates ADME/T values of a compound with respect to a reference compound (RC) on the basis of their molecular properties such as molecular weight (MW), hydrogen bond donor (HD), hydrogen bond acceptor (HA), lipophilicity (LP), and polar solvent accessibility (PSA) and creates a comparative chart of ADME/T values for both the compounds. ADME/T (Absorption, Distribution, Metabolism, Excretion, and Toxicity) values were calculated with the help of APOD for all the 15 compounds that were screened after ligand based virtual screening and it was found that only 12 of them ( Table 2) showed better results than oseltamivir (RC1) in terms of Distribution, Metabolism and Excretion, whereas Absorption and Toxicity values of these compounds were found same as of oseltamivir (RC1). Interaction maps of the compounds that showed better results after ADME/T filtering are shown in Fig. 4A -L.
Conclusions
Virtual screening methods are widely used for reducing cost and time of drug discovery process. In this study, we used only oseltamivir standards (various scores and binding energy) as a cutoff for screening of new and potential inhibitors because oseltamivir is an FDA approved drug and was discovered via structure based approach [20, 9] , and when we set oseltamivir as a standard for screening other known inhibitors (zanamivir, peramivir, and laninamivir) the possibility of success of this approach in identification of true positive inhibitors was 100%, because it was able to screen all the three other known inhibitors as true positive, whereas on using other inhibitors as standard the rate of success had decreased. This approach was successful in identifying 15 compounds which may behave as potential inhibitors. These compounds were screened via three screening platforms (MVD, PyRx, and FRED). The docked poses of these compounds resemble similar orientation as observed with neuraminidase ligand (oseltamivir). These ligands were docked deeply inside the binding pocket of NA forming interactions with ARG118, ASP151, ARG152, ARG156, TRP178, SER179, ILE222, ARG224, SER246, GLU276, and GLU277 [20] . These compounds were further filtered by their in silico ADME/T (Absorption, Distribution, Metabolism, Excretion, and Toxicity) values and only 12 of them were found as comparatively better than or as potential as oseltamivir. Therefore, this study shows the importance of this hypothesis in screening of small molecule libraries and their use to intensify drug discovery process before synthesis.
